WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY

WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY

Saved in:

Bibliographic Details
Main Authors:	Hiddo J.L. Heerspink, David C. Wheeler, Ricardo Correa-Rotter, Jamie P. Dwyer, Anna Maria Langkilde, Patrick B. Mark, Michal Nowicki, Peter Rossing, Robert D. Toto, Glenn M. Chertow, Niels Jongs
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924004443
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of dapagliflozin on podocyte damage and oxidative stress in patients with diabetic nephropathy
by: Yajing Shi, et al.
Published: (2025-08-01)

WCN24-186 JAK/STAT EXPRESSION IN PATIENTS WITH IGA NEPHROPATHY
by: Mateus Luvizotto, et al.
Published: (2024-04-01)

Topografia do cone medular do quati (Nasua nasua Linnaeus, 1766)
by: Érika Branco, et al.
Published: (2010-04-01)

WCN25-2620 CUMULATIVE EFFECTS OF THE ALDOSTERONE SYNTHASE INHIBITOR VICADROSTAT COMBINED WITH EMPAGLIFLOZIN ON ALBUMINURIA IN PEOPLE WITH CKD
by: Peter Rossing, et al.
Published: (2025-02-01)

Artérias mesentéricas cranial e caudal da paca (Cuniculus paca, L. 1766)
by: Isabela Cristina de Souza Marques, et al.
Published: (2012-10-01)

WCN24-1358 IL-1β and NLRP3 gene expression profile with dapagliflozin in inactive Lupus Nephritis
by: Gisele Vajgel, et al.
Published: (2024-04-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

WCN24-2271 WARFARINRELATED NEPHROPATHY IN TWO PATIENTS WITH MECHANICAL VALVES
by: Hong Cheng, et al.
Published: (2024-04-01)

Codex Theresianus of 1766: Codification Works, Structure, main Content and Significance of Roman Law Reception during its Conclusion Process
by: Roman Savuliak
Published: (2023-11-01)

NEW INDICATION REGISTERED FOR THE MEDICINE FORCIGA® (DAPAGLIFLOZIN): CHRONIC KIDNEY DISEASE
Published: (2022-01-01)

Cost-effectiveness of dapagliflozin for the treatment of heart failure: a systematic review
by: Zehui Jiang, et al.
Published: (2025-05-01)

WCN24-1061 ACUTE INTERSTITIAL NEPHROPATHY: CLINICAL-HISTOLOGICAL AND THERAPEUTIC ASPECTS
by: Nermine Ben Achour, et al.
Published: (2024-04-01)

Propriedades morfológicas do peritônio da paca (Cuniculus paca, L. 1766) a fresco e conservados em glicerina 98%
by: Angela Daniele De Camargo, et al.
Published: (2012-09-01)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis
by: Karun Badwal, et al.
Published: (2018-01-01)

Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain
by: Carlos Escobar, et al.
Published: (2025-07-01)

WCN24-2238 EXOSTOSIN 1- AND 2- POSITIVE MEMBRANOUS NEPHROPATHY IN CHINESE PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2478 PODOCYTOPATHY ASSOCIATED WITH IGA NEPHROPATHY: IS IT REALLY A PROGNOSTIC FACTOR?
by: BELENGALLEGOS VAZQUEZ, et al.
Published: (2024-04-01)

The genome sequence of the European ground squirrel, Spermophilus citellus (Linnaeus, 1766) [version 1; peer review: 2 approved, 1 approved with reservations]
by: Dionisios Youlatos, et al.
Published: (2025-04-01)

WCN24-2243 GERIATRIC SYNDROMES AND DECISION MAKING IN PATIENTS REFERRED TO A GERIATRIC NEPHROLOGY CLINIC
by: Jorge I. Fonseca-Correa, et al.
Published: (2024-04-01)

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial
by: Mohammad Abdel Jawad, et al.
Published: (2025-07-01)

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Efficacy and safety of dapagliflozin combined with Bailing Capsule in treatment of patients with diabetic kidney disease
by: SUI Yingying, ZHOU Quan, HAN Yafei, SUN Jialin, HAN Zhiwu
Published: (2025-08-01)

Identification of lipid metabolism-related genes in dapagliflozin treated rats with diabetic cardiomyopathy by bioinformatics
by: Xun Huang, et al.
Published: (2025-03-01)

WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK
by: Sradha Kotwal, et al.
Published: (2025-02-01)

WCN24-2320 ANALYSIS OF CLINICOPATHOLOGICAL CHARACTERISTICS OF MEMBRANOUS NEPHROPATHY WITH CONCOMITANT MALIGNANCY AND LITERATURE REVIEW
by: Hong Cheng, et al.
Published: (2024-04-01)

Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin following an Admission for Acute Heart Failure
by: Gema Miñana, et al.
Published: (2025-01-01)

Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow)
by: M. B. Antsiferov, et al.
Published: (2025-02-01)

Stability indicating green micellar liquid chromatographic method for simultaneous analysis of Metformin and dapagliflozin in their tablets
by: Aya A. Marie, et al.
Published: (2025-06-01)

The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats
by: Seyhmus Tan, et al.
Published: (2025-06-01)

Dynamics of chronic heart failure with a low ejection fraction when dapagliflozin is included in standard therapy
by: A. A. Tsareva, et al.
Published: (2024-04-01)

WCN24-1159 TREATMENT PATTERNS IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY - EVIDENCE FROM REAL-WORLD DATA
by: Serge Smeets, et al.
Published: (2024-04-01)

WCN24-2086 Demethylzeylasteral serum concentration was proved as Tripterygium Glycosides effects Biomarker on diabetic nephropathy treatment
by: MAO YONGHUI, et al.
Published: (2024-04-01)

WCN24-743 BLIND SPOT IN THE RADAR OF MEST-C SCORE: TYPE AND SEVERITY OF TUBULOINTERSTITIAL NEPHRITIS IN IGA NEPHROPATHY
by: Aurangzeb Afzal, et al.
Published: (2024-04-01)

Impact of dapagliflozin administration on remodeling marker and clinical outcomes of stemi patients with diabetes mellitus: a controlled clinical trial
by: Abdullah Heshmat, et al.
Published: (2025-08-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Clinical and economic analysis of the use of the medicinal product dapagliflozin in patients with chronic heart failure and type 2 diabetes mellitus
by: M. V. Zhuravleva, et al.
Published: (2024-07-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

WCN24-2599 EFFICACY AND SAFETY OF BUDESONIDE IN IGA NEPHROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
by: João Lucas de Magalhães Leal Moreira, et al.
Published: (2024-04-01)

WCN24-412 THE INFLUENCE OF ANGIOPOIETIN-LIKE PROTEIN 3 ON MACROPHAGES POLARIZATION AND ITS EFFECT ON THE PODOCYTE EMT IN DIABETIC NEPHROPATHY
by: Yanli Ma, et al.
Published: (2024-04-01)

WCN24-2220 A DOUBLE HIT: CASE OF THROMBOTIC MICROANGIOPATHY CONCURRENT WITH MEMBRANOUS NEPHROPATHY IN A PATIENT WITH MYELOPROLIFERATIVE NEOPLASM
by: Yuliya Sharakova
Published: (2024-04-01)